Related Experiment Video
Updated: Jun 17, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Cancer vaccine development: designing tumor cells for greater immunogenicity
Erica N Bozeman1, Rangaiah Shashidharamurthy, Simon A Paulos
1Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA.
Abstract:
Cancer vaccine development is one of the most hopeful and exhilarating areas in cancer research. For this reason, there has been a growing interest in the development and application of novel immunotherapies for the treatment of cancer with the focus being on stimulating the immune system to target tumor cells specifically while leaving normal cells unharmed. From such research has emerged a host of promising immunotherapies such as dendritic cell-based vaccines, cytokine therapies and gene transfer technology. These therapies seek to counteract the poor immunogenicity of tumors by augmenting the host's immune system with a variety of immunostimulatory proteins such as cytokines and costimulatory molecules. While such therapies have proven effective in the induction of anti-tumor immunity in animal models, they are less than optimal and pose a high risk of clinical infeasibility. Herein, we further discuss these immunotherapies as well as a feasible and efficient alternative that, in pre-clinical animal models, allows for the expression of specific immunostimulatory molecules on the surface of tumor cells by a novel protein transfer technology.
Insights
Novel cancer vaccines aim to harness the immune system against tumors. A new protein transfer technology shows promise in pre-clinical models for expressing immunostimulatory molecules on tumor cells, offering a feasible alternative to current immunotherapies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer vaccine development is a rapidly advancing field focused on stimulating the immune system to target cancer cells.
- Current immunotherapies like dendritic cell vaccines and cytokine therapies aim to enhance anti-tumor responses but face limitations in efficacy and clinical feasibility.
- Tumor cells often exhibit poor immunogenicity, necessitating strategies to augment the host immune system.
Purpose of the Study:
- To review existing immunotherapies for cancer treatment.
- To introduce and discuss a novel protein transfer technology for cancer vaccine development.
- To evaluate the potential of this new technology as a feasible and efficient alternative in pre-clinical models.
Main Methods:
- Review of current cancer immunotherapy approaches.
- Discussion of a novel protein transfer technology for expressing immunostimulatory molecules.
- Evaluation of the technology in pre-clinical animal models.
Main Results:
- Existing immunotherapies, while promising in animal models, have suboptimal outcomes and clinical feasibility challenges.
- The novel protein transfer technology enables the expression of specific immunostimulatory molecules on tumor cell surfaces.
- This technology has demonstrated feasibility and efficiency in pre-clinical animal models.
Conclusions:
- Novel immunotherapies are crucial for effective cancer treatment.
- The discussed protein transfer technology presents a promising and feasible approach for cancer vaccine development.
- Further research into this technology could lead to improved anti-tumor immunity and clinical outcomes.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy